Open-label Phase 1b pilot study to assess the antiviral efficacy of simvastatin combined with sertraline in chronic hepatitis C patients

Antiviral Therapy

Volumn 16, Issue 8, 2011, Pages 1341-1346

  Patel, Keyur ^a   Lim, Seng G ^b   Cheng, Chow W ^c   Lawitz, Eric ^d   Tillmann, Hans L ^a   Chopra, Narinder ^e   Altmeyer, Ralf ^f   Randle, John C R ^f   McHutchison, John G ^a  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b NATIONAL UNIVERSITY HOSPITAL   (Singapore)

^c SINGAPORE GENERAL HOSPITAL   (Singapore)

^d Alamo Medical Research   (United States)

^e CombinatoRx Inc ^*  (Singapore)

^f Department of Preclinical Development and Formulations   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SERTRALINE; SIMVASTATIN; VIRUS RNA;

ADULT; AGED; ANTIVIRAL ACTIVITY; ARTICLE; CAUCASIAN; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GENOTYPE; HEADACHE; HEPATITIS C; HUMAN; IN VIVO STUDY; MALE; PHASE 1 CLINICAL TRIAL; PILOT STUDY; PRIORITY JOURNAL; RELAPSE; SIDE EFFECT; SINGAPORE; TREATMENT DURATION; UNITED STATES;

ADULT; ANTIVIRAL AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; HYPOLIPIDEMIC AGENTS; INTERFERON-ALPHA; MALE; MIDDLE AGED; PILOT PROJECTS; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RIBAVIRIN; RNA, VIRAL; SEROTONIN UPTAKE INHIBITORS; SERTRALINE; SIMVASTATIN; SINGAPORE; UNITED STATES;

EID: 83455179380     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1898     Document Type: Article

References (19)

1. Ye J, Wang C, Sumpter R, Jr., Brown MS, Goldstein JL, Gale M, Jr. Disruption of hepatitis C virus RNA replication through inhibition of host protein geranylgeranylation. Proc Natl Acad Sci U S A 2003; 100:15865-15870. (Pubitemid 38021081)
2. Ikeda M, Abe K, Yamada M, Dansako H, Naka K, Kato N. Different anti-HCV profiles of statins and their potential for combination therapy with interferon. Hepatology 2006; 44:117-125. (Pubitemid 44049145)
3. Delang L, Paeshuyse J, Vliegen I, et al. Statins potentiate the in vitro anti-hepatitis C virus activity of selective hepatitis C virus inhibitors and delay or prevent resistance development. Hepatology 2009; 50:6-16.
4. Harrison SA, Rossaro L, Hu KQ, et al. Serum cholesterol and statin use predict virological response to peginterferon and ribavirin therapy. Hepatology 2010; 52:864-874.
5. Bader T, Fazili J, Madhoun M, et al. Fluvastatin inhibits hepatitis C replication in humans. Am J Gastroenterol 2008; 103:1383-1389. (Pubitemid 351813920)
6. Milazzo L, Meroni L, Galazzi M, et al. Does fluvastatin favour HCV replication in vivo? A pilot study on HIV-HCV coinfected patients. J Viral Hepat 2009; 16:479-484.
7. Letendre SL, Marquie-Beck J, Ellis RJ, et al. The role of cohort studies in drug development: clinical evidence of antiviral activity of serotonin reuptake inhibitors and HMG-CoA reductase inhibitors in the central nervous system. J Neuroimmune Pharmacol 2007; 2:120-127.
8. Glassman AH, O'Connor CM, Califf RM, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA 2002; 288:701-709. (Pubitemid 34848222)
9. Bergman AJ, Murphy G, Burke J, et al. Simvastatin does not have a clinically significant pharmacokinetic interaction with fenofibrate in humans. J Clin Pharmacol 2004; 44:1054-1062. (Pubitemid 39096820)
10. Schachter M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam Clin Pharmacol 2005; 19:117-125. (Pubitemid 40204354)
11. Owens CM, Mawhinney C, Grenier JM, et al. Chemical combinations elucidate pathway interactions and regulation relevant to Hepatitis C replication. Mol Syst Biol 2010; 6:375.
12. O'Leary JG, Chan JL, McMahon CM, Chung RT. Atorvastatin does not exhibit antiviral activity against HCV at conventional doses: a pilot clinical trial. Hepatology 2007; 45:895-898. (Pubitemid 46631558)
13. Patel K, Jhaveri R, George J, et al. Open-label, ascending dose, prospective cohort study evaluating the antiviral efficacy of Rosuvastatin therapy in serum and lipid fractions in patients with chronic hepatitis C. J Viral Hepat 2011; 18:331-337.
14. de Denus S, Spinler SA, Miller K, Peterson AM. Statins and liver toxicity: A meta-analysis. Pharmacotherapy 2004; 24:584-591. (Pubitemid 38585952)
15. Palinski W. Immunomodulation: a new role for statins? Nat Med 2000; 6:1311-1312. (Pubitemid 32001000)
16. Molina S, Castet V, Fournier-Wirth C, et al. The low-density lipoprotein receptor plays a role in the infection of primary human hepatocytes by hepatitis C virus. J Hepatol 2007; 46:411-419. (Pubitemid 46201721)
17. Petit JM, Minello A, Duvillard L, et al. Cell surface expression of LDL receptor in chronic hepatitis C: correlation with viral load. Am J Physiol Endocrinol Metab 2007; 293:E416-E420. (Pubitemid 47105957)
18. Ikeda M, Kato N. Life style-related diseases of the digestive system: Cell culture system for the screening of antihepatitis C virus (HCV) reagents: Suppression of HCV replication by statins and synergistic action with interferon. J Pharmacol Sci 2007; 105:145-150. (Pubitemid 350106803)
19. Sezaki H, Suzuki F, Akuta N, et al. An open pilot study exploring the efficacy of fluvastatin, pegylated interferon and ribavirin in patients with hepatitis C virus genotype 1b in high viral loads. Intervirology 2009; 52:43-48.